Cargando…
A Pilot Analysis of Circulating cfRNA Transcripts for the Detection of Lung Cancer
Lung cancers are the leading cause of cancer-related deaths worldwide. Studies have shown that non-small cell lung cancer (NSCLC), which constitutes the majority of lung cancers, is significantly more responsive to early-stage interventions. However, the early stages are often asymptomatic, and curr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776862/ https://www.ncbi.nlm.nih.gov/pubmed/36552904 http://dx.doi.org/10.3390/diagnostics12122897 |
_version_ | 1784855963117813760 |
---|---|
author | Seneviratne, Chamindi Shetty, Amol Carl Geng, Xinyan McCracken, Carrie Cornell, Jessica Mullins, Kristin Jiang, Feng Stass, Sanford |
author_facet | Seneviratne, Chamindi Shetty, Amol Carl Geng, Xinyan McCracken, Carrie Cornell, Jessica Mullins, Kristin Jiang, Feng Stass, Sanford |
author_sort | Seneviratne, Chamindi |
collection | PubMed |
description | Lung cancers are the leading cause of cancer-related deaths worldwide. Studies have shown that non-small cell lung cancer (NSCLC), which constitutes the majority of lung cancers, is significantly more responsive to early-stage interventions. However, the early stages are often asymptomatic, and current diagnostic methods are limited in their precision and safety. The cell-free RNAs (cfRNAs) circulating in plasma (liquid biopsies) offer a non-invasive detection of spatial and temporal changes occurring in primary tumors since the early stages. To address gaps in the current cfRNA knowledge base, we conducted a pilot study for the comprehensive analysis of transcriptome-wide changes in plasma cfRNA in NSCLC patients. Total cfRNA was extracted from archived plasma collected from NSCLC patients (N = 12), cancer-free former smokers (N = 12), and non-smoking healthy volunteers (N = 12). Plasma cfRNA expression levels were quantified by using a tagmentation-based library preparation and sequencing. The comparisons of cfRNA expression levels between patients and the two control groups revealed a total of 2357 differentially expressed cfRNAs enriched in 123 pathways. Of these, 251 transcripts were previously reported in primary NSCLCs. A small subset of genes (N = 5) was validated in an independent sample (N = 50) using qRT-PCR. Our study provides a framework for developing blood-based assays for the early detection of NSCLC and warrants further validation. |
format | Online Article Text |
id | pubmed-9776862 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97768622022-12-23 A Pilot Analysis of Circulating cfRNA Transcripts for the Detection of Lung Cancer Seneviratne, Chamindi Shetty, Amol Carl Geng, Xinyan McCracken, Carrie Cornell, Jessica Mullins, Kristin Jiang, Feng Stass, Sanford Diagnostics (Basel) Article Lung cancers are the leading cause of cancer-related deaths worldwide. Studies have shown that non-small cell lung cancer (NSCLC), which constitutes the majority of lung cancers, is significantly more responsive to early-stage interventions. However, the early stages are often asymptomatic, and current diagnostic methods are limited in their precision and safety. The cell-free RNAs (cfRNAs) circulating in plasma (liquid biopsies) offer a non-invasive detection of spatial and temporal changes occurring in primary tumors since the early stages. To address gaps in the current cfRNA knowledge base, we conducted a pilot study for the comprehensive analysis of transcriptome-wide changes in plasma cfRNA in NSCLC patients. Total cfRNA was extracted from archived plasma collected from NSCLC patients (N = 12), cancer-free former smokers (N = 12), and non-smoking healthy volunteers (N = 12). Plasma cfRNA expression levels were quantified by using a tagmentation-based library preparation and sequencing. The comparisons of cfRNA expression levels between patients and the two control groups revealed a total of 2357 differentially expressed cfRNAs enriched in 123 pathways. Of these, 251 transcripts were previously reported in primary NSCLCs. A small subset of genes (N = 5) was validated in an independent sample (N = 50) using qRT-PCR. Our study provides a framework for developing blood-based assays for the early detection of NSCLC and warrants further validation. MDPI 2022-11-22 /pmc/articles/PMC9776862/ /pubmed/36552904 http://dx.doi.org/10.3390/diagnostics12122897 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Seneviratne, Chamindi Shetty, Amol Carl Geng, Xinyan McCracken, Carrie Cornell, Jessica Mullins, Kristin Jiang, Feng Stass, Sanford A Pilot Analysis of Circulating cfRNA Transcripts for the Detection of Lung Cancer |
title | A Pilot Analysis of Circulating cfRNA Transcripts for the Detection of Lung Cancer |
title_full | A Pilot Analysis of Circulating cfRNA Transcripts for the Detection of Lung Cancer |
title_fullStr | A Pilot Analysis of Circulating cfRNA Transcripts for the Detection of Lung Cancer |
title_full_unstemmed | A Pilot Analysis of Circulating cfRNA Transcripts for the Detection of Lung Cancer |
title_short | A Pilot Analysis of Circulating cfRNA Transcripts for the Detection of Lung Cancer |
title_sort | pilot analysis of circulating cfrna transcripts for the detection of lung cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776862/ https://www.ncbi.nlm.nih.gov/pubmed/36552904 http://dx.doi.org/10.3390/diagnostics12122897 |
work_keys_str_mv | AT seneviratnechamindi apilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer AT shettyamolcarl apilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer AT gengxinyan apilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer AT mccrackencarrie apilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer AT cornelljessica apilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer AT mullinskristin apilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer AT jiangfeng apilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer AT stasssanford apilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer AT seneviratnechamindi pilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer AT shettyamolcarl pilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer AT gengxinyan pilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer AT mccrackencarrie pilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer AT cornelljessica pilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer AT mullinskristin pilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer AT jiangfeng pilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer AT stasssanford pilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer |